bortezomib,lenalidomide,dexamethasone
bms
['mpnsm', 'determination', '#mpn']
congress #eha2022 lba: paul richardson, on ph3 determination trial. significantly longer pfs with rvd+asct vs rvd alone. no os benefit after &gt;6 years follow-up. similar orr rates (97.5% vs 95%). rvd+asct was generally manageable but sign. rates of tox #mpnsm 
The Multiple Myeloma (MM) Hub is an online educational resource run in collaboration with the European School of Haematology @ESHaematology #mmsm #myeloma